AVM0703 selectively ablates T and B lymphocytes and monocytes, and lymphodepletes neutrophils at the target clinical dose. Basophils (reduced only at the 6 hour time point) and eosinophils (reduced only at the 24 and 48 hour time points), platelets, RBCs are spared, and HSC and MSC are spared or increased.
We at AVM believe that there should be a treatment option that allows you to have a good quality of life with your loved ones without exhausting your finances.
The ability to replace toxic chemotherapy represents an investing and partnering opportunity that is not only significant in monetary value but also impactful in social value.
In the U.S. alone, total patients who can be treated with AVM0703 represent a $30B dollar annual revenue opportunity.
We are here to develop products that will end human exploitation in biomedical research and medical treatments.
Human exploitation can be physical, for instance, black market sales of organs for transplant; it can be financial, for example, the financial toxicities of the newer cancer and autoimmunity treatments because of their high non-reimbursed price tags; it can be neglect, for instance, the absence of uninjurious medical options for vulnerable patient populations such as the elderly, children, the poor or disabled. For example, children treated with chemotherapy have a 3 to 13 fold increased risk of getting another cancer within 20-30 years of treatment, yet, chemotherapy remains the standard regimen for children.
